Home > Insider Trading > Filing (0000904454-20-000426)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1805890	Fusion Pharmaceuticals Inc.	FUSN	Pharmaceutical Preparations (2834)	NJ

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
200406	Johnson & Johnson	One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933		No	No	Yes	No
924020	Johnson & Johnson Innovation - Jjdc, Inc.	410 George Street New Brunswick NJ 08901		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-06-30	2,945,516	$0.00	2,945,516	No	4	C	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.
Common Shares	Acquisiton	2020-06-30	725,000	$17.00	3,670,516	No	4	P	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.
No	4	P	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Class A Preferred Shares	Disposition	2020-06-30	10,666,667	$0.00	1,997,876	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-30	5,059,460	$0.00	947,640	$0.00
Class B Preferred Shares	Warrants to purchase Class B Preferred Shares	Disposition	2020-06-30	475,802	$0.00	475,802	$0.00
Common Shares	Warrants to purchase Common Shares	Acquisiton	2020-06-30	89,118	$0.00	89,118	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	C	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect
89,118	No	4	C	Indirect

Footnotes

The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date.
The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share.